Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neutropenia × Antiviral Agents × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2 Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Neutropenia 1 Neoplasms 1 Myeloproliferative Disorders 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Leukemia, Prolymphocytic 1 Leukemia, Neutrophilic, Chronic 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid, Accelerated Phase 1

Interventions

pegfilgrastim 30 Filgrastim 29 Cyclophosphamide 10 pegylated granulocyte colony-stimulating factor 8 Docetaxel 8 Etoposide 7 Cytarabine 7 Leucovorin 5 Fluorouracil 5 Ciprofloxacin 5 Cefepime 5 eflapegrastim 4 Vancomycin 4 Granulocyte Colony-Stimulating Factor 4 Doxorubicin 4 Peripheral Blood Stem Cell Transplantation 3 Mitoxantrone 3 Methotrexate 3 Levofloxacin 3 Irinotecan 3 Idarubicin 3 Daunorubicin 3 Cyclosporine 3 Caspofungin 3 Carboplatin 3 trifluridine tipiracil drug combination 2 plerixafor 2 liposomal amphotericin B 2 Vincristine 2 Topotecan 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01821456 2013-04-01

CoCoNut

University Hospital of Cologne

100,000 enrolled

Other hematologic neoplasm

Neoplasms, Neutropenia, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡